SanBio Co Ltd

SanBio is a pioneering cell therapy company developing regenerative treatments for severe CNS injuries and disorders with high unmet medical need. Its core technology platform utilizes modified allogeneic bone marrow-derived mesenchymal stem cells (SB623) designed to be surgically implanted into the brain to stimulate natural repair processes. The company's lead program has achieved significant clinical milestones, including a conditional approval in Japan for TBI, positioning it as a leader in the neuro-regenerative medicine space. SanBio emphasizes scalable manufacturing and a global development strategy to bring accessible cell therapies to a broad patient population.

Allogeneic bone marrow-derived mesenchymal stem cells (MSCs) genetically modified with the Notch-1 intracellular domain (SB623 cells). Platform focuses on scalable manufacturing for off-the-shelf cell therapy.

SanBio operates in the emerging neuro-regenerative medicine space. Direct competitors include other companies developing cell therapies (e.g., stem cells) for stroke and TBI, though few are as advanced in late-stage trials. Indirect competition comes from neuro-rehabilitation devices, pharmaceuticals for symptom management, and other neuromodulation approaches. SanBio's differentiation is its specific MSC technology, surgical delivery for localized treatment, and advanced progress towards commercialization in Japan.